SYSTEMATIC REVIEW



Norepinephrine versus phenylephrine for managing maternal hypotension during cesarean delivery under spinal anesthesia: a meta-analysis of maternal and neonatal outcomes

Jianli Song¹, Xi Xu², Qiang Li¹, Bin Lu¹, Xuan Yu¹, Guo Mu^{1,*}

¹Department of Anesthesiology, Zigong Fourth People's Hospital, 643000 Zigong, Sichuan, China ²Department of Anesthesiology, The Fushun People's Hospital, 643000 Zigong, Sichuan, China

*Correspondence muguo@zg120.cn (Guo Mu)

Abstract

Norepinephrine or phenylephrine administration to prevent and treat hypotension during spinal anesthesia for cesarean section has been a significant topic of discussion. This meta-analysis aimed to update existing evidence and provide further insights into neonatal and maternal outcomes associated with norepinephrine and phenylephrine. Review of randomized controlled trials (RCTs) was performed to assess the effectiveness of norepinephrine and phenylephrine in managing maternal hypotension during cesarean delivery under spinal anesthesia. Neonatal umbilical cord blood pH and maternal hypotension were the primary outcomes. Based on the analysis of 26 RCTs with 2984 participants, we found no significant difference between the norepinephrine and phenylephrine groups in umbilical artery pH in neonates (mean difference (MD) 0.00; 95% confidence interval (CI) -0.00 to 0.01, p = 0.20). Neonates Apgar scores did not differ between both groups. Norepinephrine was associated with lower incidences of bradycardia (risk ratio (RR) 0.44; 95% CI 0.37 to 0.51, p < 0.001) and reactive hypertension (RR 0.53; 95% CI 0.39 to 0.72, p < 0.001) in parturient women than phenylephrine. In neither group did umbilical cord blood levels of partial pressure of oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂) and base excess (BE) levels of neonates differ significantly, nor did maternal hypotension, nausea or vomiting incidence during delivery. For maternal hypotension after spinal anesthesia, norepinephrine and phenylephrine did not significantly differ in neonatal acidemia. Despite similarities to phenylephrine in managing hypotension and maintaining maternal hemodynamic stability, norepinephrine is a promising alternative.

Keywords

Norepinephrine; Phenylephrine; Maternal hypotension; Caesarean delivery; Spinal anesthesia

1. Introduction

Spinal anesthesia is considered the preferred technique for both elective and emergency cesarean sections due to its excellent operative conditions and high tolerance levels [1]. However, hypotension remains a common spinal anesthesia complication. Post-spinal hypotension incidence can reach 70–80% without prophylactic vasoactive drugs [2]. Maternal symptoms of severe hypotension include nausea, vomiting and dyspnea. Hypotension severity and duration are associated with adverse effects on newborns, such as reduced Apgar scores and acidosis [3]. Therefore, maternal hypotension should be prevented efficiently.

A recent standard of care recommends prophylactic use of vasopressors and fluid boluses [4–6]. Phenylephrine, a potent alpha-adrenergic receptor agonist, has emerged as a pri-

mary vasopressor in obstetrics [5, 7]. Baroreceptor-mediated bradycardia and maternal cardiac output reductions are possible side effects [8, 9]. There is no evidence that these changes have adverse effects on neonates at the moment. Nevertheless, researchers have raised concerns regarding the lack of appropriate assessment techniques and longer followups [10]. Norepinephrine, a strong alpha-adrenergic receptor agonist with beta-adrenergic effects, has been found to be equivalent to phenylephrine in maintaining blood pressure while increasing heart rate (HR) and cardiac output (CO) [8, 11]. Based on systematic evaluations, norepinephrine offers better hemodynamic stability and fewer side effects in controlling maternal hypotension than phenylephrine [12]. However, these evaluations were based on small-sample studies that rarely examined norepinephrine's impact on fetal acid-base status. A single Bayesian network meta-analysis indicated that norepinephrine adversely affected fetal acid-base status less frequently [13]. Moreover, the effectiveness of norepinephrine and phenylephrine in managing maternal hypotension during cesarean sections was recently evaluated in randomized controlled trials using neonatal outcomes as the primary research indicator [14–16].

This study conducted a systematic review and metaanalysis to update existing evidence and better understand norepinephrine's effects on neonatal and maternal outcomes. We aimed to develop updated evidence-based guidelines for anesthesiologists to treat and prevent maternal hypotension during cesarean sections under spinal anesthesia on the selection of norepinephrine and phenylephrine.

2. Methods

This study adhered to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) [17]. The protocol was registered in the International Prospective Register of Systematic Reviews (PROS-PERO) under Registration ID CRD42022361087.

2.1 Outcomes

We evaluated neonatal and maternal outcomes separately. In neonatal assessment, umbilical cord blood pH (including that of the umbilical artery and vein) was the primary indicator. Umbilical cord PaO₂, PaCO₂ and base excess (BE), umbilical artery lactate, and APGAR scores of neonates at 1 minute and 5 minutes were secondary outcomes. A prespecified subgroup analysis was performed to determine whether prophylactic infusion or bolus therapy of norepinephrine or phenylephrine affected maternal and neonatal outcomes in treating maternal hypotension.

In maternal assessment, the incidence of hypotension was the primary outcome. Hypotension is defined as a reduction in blood pressure even when norepinephrine or phenylephrine is administered. In the enrolled studies, hypotension was commonly referred to as "<80% baseline systolic blood pressure (SBP)" or "<100 mmHg". The incidence of bradycardia, nausea, vomiting and reactive hypertension were secondary outcomes. The majority of studies defined bradycardia by HR <60 beats/min, with only six studies using HR <50 beats/min. In almost all included studies, reactive hypertension was defined as SBP >120% of the baseline value.

2.2 Selection and exclusion criteria

A meticulously search was conducted on PubMed, Web of Science and Cochrane Library, spanning their inception until 18 September 2022. **Supplementary Table 1** outlines the detailed search strategy. Clinical trial registries were explored to identify grey literature. A comprehensive review of all included studies' reference lists was conducted to ensure no studies had been overlooked in the initial electronic search. Language, sample size or publication date were not restricted. The inclusion criteria were: (1) population—parturient women undergoing spinal anesthesia elective cesarean delivery, (2) intervention—intraoperative norepinephrine intraoperatively to manage or prevent post-spinal hypotension, (3) control—phenylephrine intraoperatively to manage or prevent post-spinal hypotension, (4) outcomes—eligible studies reporting at least one predetermined outcome, and
(5) study design—randomized controlled trials. Exclusion criteria included (1) general anesthesia cesarean deliveries,
(2) failure to extract data, and (3) lack of full text access.

2.3 Data extraction

Potential inclusions were independently screened by Jianli Song and Xi Xu. All potentially eligible studies were reviewed in detail, and data was extracted using an Excel spreadsheet extraction table. Basic information, treatment methods and outcome indicators were meticulously collected from articles that met the criteria. The two reviewers resolved any disagreements through discussion or mediation by Guo Mu.

2.4 Risk of bias assessment

Using the Cochrane Collaboration risk-of-bias tool, two reviewers independently assessed the bias risk of the included studies. Study bias was classified as high, low or unclear. For consistency, each study underwent cross-checking, and discrepancies were resolved by involving a third reviewer as a mediator or a discussion between the two reviewers.

2.5 Statistical analysis

In each study, continuous and dichotomous data were extracted. Continuous data were presented as mean difference (MD) with a 95% confidence interval (CI). Dichotomous data were presented as a risk ratio (RR) with a 95% CI. Using Wan et al.'s [18] method, studies with median and range or interquartile range were converted to mean and standard deviation [18]. Statistical heterogeneity was evaluated using I^2 statistics. A fixed-effects model was applied, and a random-effects model was adopted in cases of significant heterogeneity (p-value of chi-square test < 0.10 and $I^2 > 50\%$). To investigate heterogeneity sources, subgroup and sensitivity analyses were performed when heterogeneity was high. One study at a time was omitted during the sensitivity analysis to determine its impact on the overall pooled estimate. Considering clinical and methodological diversity among studies, a random-effects model was used to analyze the effect sizes of primary and secondary outcomes. Over 10 studies were evaluated for potential publication bias using funnel plot symmetry. We pre-planned a subgroup analysis based on drug administration protocol (prophylactic infusion versus bolus treatment for maternal hypotension) in anticipation of heterogeneity across trials. Statistical studies and meta-analyses were conducted with Review Manager (RevMan, V.5.4.1), with a two-sided statistical significance set at p < 0.05.

3. Results

3.1 Search outcomes and study characteristics

This meta-analysis included 26 RCTs. An initial electronic search yielded 894 citations, and a review of gray literature added 33 more. A thorough text review of 54 studies was

identified as potentially eligible. After eliminating duplicates and disqualified studies, this meta-analysis included 26 RCTs with 2984 participants [8, 14–16, 19–40] (Fig. 1A). This analysis includes studies from 2015 to 2022, with sample sizes ranging from 44 to 668 patients. Among the considered studies, 14 trials used norepinephrine or phenylephrine as a prophylactic infusion to prevent maternal hypotension [8, 15, 16, 19–29], 9 used bolus administration for treatment [14, 30– 37], 2 used bolus administration for prevention or treatment [38, 39], and 1 used an infusion or bolus for either prophylactic or therapeutic purposes [40]. Using a literature-by-exclusion approach, sensitivity analyses were conducted on outcomes exhibiting high heterogeneity. Fig. 1B,C summarizes the risk of bias for individual studies and the overall risk of bias. Table 1 summarizes the key features of the included studies.




FIGURE 1. Literature inclusion process and quality evaluation. (A) PRISMA flow diagram of study selection. (B) Risk of bias summary of the included studies. (C) Risk of bias graph of the included studies. RCT: randomized controlled trial.

Trail	Country	Type of surgery	Total patients	Mode of ad- ministration	Norepinephrine group	Phenylephrine group	Primary outcome	Inclusion indicators
Ngan Kee, 2015	China	Elective CD under spinal anesthesia	101	Prophylactic infusions	Infusion rate was within the limits of 0 to 60 mL/h (5 µg/mL, n = 49)	Infusion rate was within the limits of 0 to 60 mL/h (100 µg/mL, n = 52)	СО	024367
Vallejo, 2017	USA	Elective CD under spinal anesthesia	81	Prophylactic infusions	Fixed-rate infusions at 0.05 μ g/kg/min (n = 43)	Fixed-rate infusions at 0.1 μ g/kg/min (n = 38)	The number and total dose of rescue bolus interventions	256
Dong, 2017	China	Elective CD under spinal anesthesia	126	Prophylactic infusions	50 μg was given a bolus prophylactically (10 μg/mL, n = 62)	50 μg was given a bolus prophylactically (50 μg/mL, n = 64)	Maternal hypotension	02567
Hasanin, 2019	Egypt	Elective CD under spinal anesthesia	123	Prophylactic infusions	Infusion with a starting rate of 0.05 µg/kg/min (4 µg/mL, n = 60)	Infusion with a starting rate of 0.75 μg/kg/min (50 μg/mL, n = 63)	Post-spinal hypotension	034567
Mohta, 2019	India	Elective CD under spinal anesthesia	90	Bolus for treatment	5 μ g was given a bolus for treatment (5 μ g/mL, n = 45)	100 μ g was given a bolus for treatment (100 μ g/mL, n = 45)	Maternal bradycardia	12350
Puthenveettil, 2019	India	Elective CD under spinal anesthesia	50	Bolus for treatment	4 μ g was given a bolus for treatment (4 μ g/mL, n = 25)	50 μg was given a bolus for treatment (50 μg/mL, n = 25)	The number of bolus doses of interventions	2356
Sharkey, 2019	Canada	Elective CD under spinal anesthesia	112	Bolus for treatment	$6 \mu g$ was given a bolus for treatment ($6 \mu g/mL$, n = 56)	100 μ g was given a bolus for treatment (100 μ g/mL, n = 56)	Maternal bradycardia	1234567
Wang, 2019	China	Elective CD under spinal anesthesia in patients with pre-eclampsia	111	Bolus for treatment	4 μ g was given a bolus for treatment (4 μ g/mL, n = 56)	50 μg was given a bolus for treatment (50 μg/mL, n = 55)	The overall SBP and HR	1456
Biricik, 2020	Turkey	Elective CD under spinal anesthesia	80	Prophylactic infusion	Infusion at a fixed rate of 30 mL/h (5 μ g/mL, n = 40)	Infusion at a fixed rate of 30 mL/h (100 μ g/mL, n = 40)	Maternal hypotension	2456
Theodoraki, 2020	Greece	Elective CD under spinal anesthesia	82	Prophylactic infusion	Infusion at a fixed rate of 30 mL/h (5 μ g/mL, n = 41)	Infusion at a fixed rate of 30 mL/h (100 μ g/mL, n = 41)	Maternal bradycardia	23456

TABLE 1. Main characteristics of included studies.

				TABLE	1. Continued.			
Trail	Country	Type of surgery	Total patients	Mode of ad- ministration	Norepinephrine group	Phenylephrine group	Primary outcome	Inclusion indicators
Ngan Kee, 2020	China	Elective and non-elective CD under spinal anesthesia	668	prophylactically or therapeuti- cally	Infusion or bolus (6 μ g/mL, n = 333)	Infusion or bolus (100 μ g/mL, n = 335)	UA pH	12456
Cho, 2020	Korea	Elective CD under spinal anesthesia	44	Bolus for treatment	5 μ g was given a bolus for treatment (5 μ g/mL, n = 22)	100 μ g was given a bolus for treatment (100 μ g/mL, n = 22)	СО	136
Wang, 2020	China	Elective CD under spinal anesthesia	102	Bolus for prevention and treatment	8 μ g was given a bolus for prevention and treatment (8 μ g/mL, n = 52)	100 µg was given a bolus for prevention and treatment (100 µg/mL, n = 50)	СО	123567
Eskandr Am, 2021	Egypt	Elective CD under spinal anesthesia	50	Prophylactic infusion	Infusion at a rate of 0.05 μ g/kg/min (n = 25)	Infusions at a rate of 0.1 µg/kg/min (n = 25)	Post-spinal hypotension	1356
Goel, 2021	India	Elective CD under spinal anesthesia	200	Prophylactic infusion	Infusion rate was within the limits of 0 to 60 mL/h (NE: 5 μ g/mL, n = 100)	Infusion rate was within the limits of 0 to 60 mL/h (PE: 100 μ g/mL, n = 100)	Maternal hemodynamics	567
Mohta, 2021	India	Elective CD under spinal anesthesia in patients with pre-eclampsia	86	Bolus for treatment	4 μ g was given a bolus for treatment (4 μ g/mL, n = 43)	50 μ g was given a bolus for treatment (50 μ g/mL, n = 43)	UA pH	029
Apoorva Singh, 2022	India	Elective CD under spinal anesthesia	100	Prophylactic infusion	Infusion at a fixed-rate of 50 mL/h (6 µg/mL, n = 50)	Infusion at a fixed-rate of 50 mL/h (120 µg/mL, n = 50)	UA BE	Ū
Zhou, 2022	China	Elective CD under spinal anesthesia	50	Prophylactic infusion	Infusion at an initial rate of 30 mL/h (8 μ g/mL, n = 25)	Infusion at an initial rate of 30 mL/h (100 μ g/mL, n = 25)	UA pH	1234567
Tiwari, 2022	India	Elective CD under spinal anesthesia	126	Bolus for treatment	4 μ g was given a bolus for treatment (4 μ g/mL, n = 63)	50 μg was given a bolus for treatment (50 μg/mL, n = 63)	Post-spinal hypotension	2356
Jaskaran Singh, 2022	India	Elective CD under spinal anesthesia	60	Prophylactic infusion	Infusion at the rate of 60 mL/h (2.5 μ g/mL, n = 30)	Infusion at the rate of 60 mL/h (50 μ g/mL, n = 30)	UA pH	1234567

				TABL	E 1. Continued.			
Trail	Country	Type of surgery	Total patients	Mode of ad- ministration	Norepinephrine group	Phenylephrine group	Primary outcome	Inclusion indicators
Guo, 2022	China	Elective CD under spinal anesthesia in patients with pre-eclampsia	138	Prophylactic infusion	Fixed-rate infusions at 0.05 µg/kg/min (n = 69)	Fixed-rate infusions at 0.625 µg/kg/min (n = 69)	Maternal bradycardia and hypotension	134567
Mohta, 2022	India	Emergency CD under spinal anesthesia in patients with fetal compromise	100	Bolus for treatment	8 μg was given a bolus for treatment (8 μg/mL, n = 50)	100 μg was given a bolus for treatment (100 μg/mL, n = 50)	UA pH	1235
Du, 2022	China	Elective CD under spinal anesthesia in healthy twin pregnancies	62	Prophylactic infusion	Infusion at an initial rate of 60 mL/h (6 μ g/h, n = 31)	Infusion at an initial rate of 60 mL/h (100 μ g/h, n = 31)	СО	234567
Chen, 2022	China	Elective CD under spinal anesthesia in healthy twin pregnancies	100	Prophylactic infusion	Infusion at an initial rate of 24 mL/h (8 µg/h, n = 50)	Infusion at an initial rate of 24 mL/h (100 µg/h, n = 50)	The change in HR and BP	1234567
Liu, 2022	China	Elective CD under spinal anesthesia	52	Prophylactic infusion	Infusion at an initial rate of 0.3 μ g/kg/h (16 μ g/h, n = 26)	Infusion at an initial rate of 0.3 μ g/kg/h (108 μ g/h, n = 26)	UA pH	12456
Rai. A, 2022	India	Elective CD under spinal anesthesia	90	Bolus for treatment	1 mL was given boluses for treatment $(100 \ \mu g/mL, n = 45)$	1 mL was given boluses for treatment $(7.5 \ \mu g/mL, n = 45)$	UA pH	1257

CD: cesarean delivery; UA: umbilical artery; CO: cardiac output; SBP: systolic blood pressure; HR: heart rate; BP: blood pressure; BE: base excess. ① UA blood gas analysis, ② Umbilical venous (UV) blood gas analysis, ③ Apgar scores in 1-min and 5-min, ④ Hypotension, ⑤ Bradycardia, ⑥ Nausea or vomiting, ⑦ Reactive hypertension.

3.2 Primary outcomes of neonates: the pH of umbilical cord blood

3.2.1 Umbilical artery pH

19 studies comprising 2293 neonates reported umbilical artery pH [8, 14–16, 20, 23, 25–27, 29, 30, 32–35, 37–39]. In meta-analysis, norepinephrine did not significantly differ from phenylephrine in neonates' umbilical artery pH during cesarean section under spinal anesthesia to prevent and treat maternal hypotension. The MD (95% CI) of 0.00 (-0.00 to 0.01; p = 0.20) was observed (Fig. 2A). Subgroup analysis revealed no significant effect related to drug administration method (p = 0.63, Fig. 2B). Funnel plot analysis showed no significant asymmetry, indicating a low likelihood of publication bias (**Supplementary Fig. 1A**).

3.2.2 Umbilical venous pH

19 studies involving 2139 neonates reported umbilical venous pH. According to the meta-analysis based on these studies, norepinephrine used during cesarean section under spinal anesthesia led to higher neonates' umbilical venous pH than phenylephrine. The MD (95% CI) was 0.01 (0.00 to 0.01; p = 0.001) (Fig. 3A). Subgroup analysis suggested that the drug administration mode had no effect on umbilical venous pH in neonates, with moderate heterogeneity (p = 0.09, $I^2 = 65\%$) (Fig. 3B). Funnel plot analysis visually indicated no significant asymmetry, indicating a low probability of publication bias (**Supplementary Fig. 1B**).

3.3 Secondary neonatal outcomes

3.3.1 Umbilical cord PaO₂

18 studies involving 2233 neonates reported umbilical artery PaO₂ and 18 studies involving 2010 neonates reported umbilical venous PaO₂. The meta-analysis of the relevant 18 studies found no significant differences in neonates' umbilical artery PaO₂, with a MD (95% CI) of 0.41 mmHg (-0.46 to 1.29; p = 0.35) (Fig. 4A). Based on the other set, the meta-analysis found no significant differences in umbilical venous PaO₂, with a MD (95% CI) of 0.73 mmHg (-0.50 to 1.96; p = 0.24) (Fig. 4B).

3.3.2 Umbilical cord PaCO₂

18 studies involving 2233 neonates reported umbilical artery PaCO₂ and 18 studies involving 2148 neonates reported umbilical venous PaCO₂. A meta-analysis of 18 studies showed no significant differences in neonates' umbilical artery PaCO₂, with a MD (95% CI) of 0.22 mmHg (-0.34 to 0.79; p = 0.44) (Fig. 5A). Based on the other set, the meta-analysis found no significant differences in umbilical venous PaCO₂, with a MD (95% CI) of -0.34 mmHg (-1.41 to 0.73; p = 0.54) (Fig. 5B).

3.3.3 Umbilical cord base excess (BE)

16 studies reported umbilical artery BE in 2060 neonates and 16 studies reported umbilical venous BE in 1972 neonates. A meta-analysis of 16 studies showed no statistical differences in neonates' umbilical artery BE, with a MD (95% CI) of 0.07 (-0.19 to 0.33; p = 0.58). Based on the other set, the metaanalysis found no significant differences in neonates' umbilical

3.3.4 Umbilical artery lactate

11 studies reported umbilical artery lactate in 996 neonates. Based on these 11 studies, a meta-analysis showed no significant difference in umbilical artery lactate levels in neonates, with a MD (95% CI) of 0.04 mmol/L (-0.07 to 0.15; p = 0.47) (Supplementary Fig. 3).

3.3.5 Apgar scores of neonates

14 studies reported APGAR scores at 1 minute and 5 minutes, including 1239 neonates, and 6 reported APGAR scores <7 at 1 minute or 5 minutes, encompassing 1195 neonates. AP-GAR scores in neonates at 1 minute and 5 minutes were not significantly different based on a meta-analysis of 14 studies (**Supplementary Fig. 4A**). Moreover, no significant differences were observed in APGAR scores <7 at 1 minute and 5 minutes (**Supplementary Fig. 4B**).

3.4 Maternal primary outcomes: the incidence of hypotension after vasopressor-use

12 studies reported maternal hypotension involving 1828 parturient women. According to the meta-analysis, hypotension incidence was not significantly different between the 12 studies, with a RR (95% CI) of 1.12 (1.00 to 1.25; p =0.06) (Fig. 6A). There was no subgroup effect related to drug administration mode (p = 0.46) (Fig. 6B). Funnel plot analysis suggested visually no significant asymmetry, indicating a low probability of publication bias (**Supplementary Fig. 5**).

3.5 Maternal secondary outcomes

3.5.1 The incidence of maternal bradycardia

25 studies involving 2878 parturient women reported maternal bradycardia. According to the meta-analysis, bradycardia incidence was not significantly different between the 25 studies, with a RR (95% CI) of 0.44 (0.37 to 0.51; p < 0.001) (Fig. 7). No subgroup effect related to drug administration mode was observed (p = 0.84). Also, there were no differences in either the prophylactic infusion group (RR 0.39, 95% CI 0.29 to 0.54, p < 0.001) or the bolus group (MD 0.41, 95% CI 0.29 to 0.58, p < 0.001) (Supplementary Fig. 6).

3.5.2 The incidence of maternal nausea or vomiting

21 studies encompassing 2514 parturient women, reported maternal nausea or vomiting. Based on these 21 studies, a meta-analysis showed no significant difference in nausea or vomiting incidence, with a RR (95% CI) of 1.00 (0.85 to 1.18; p = 0.97) (Fig. 8). There was no subgroup effect related to drug administration mode (p = 0.41). Neither the prophylactic infusion group (RR 0.99, 95% CI 0.71 to 1.37, p = 0.94) or the bolus group (RR 0.79, 95% CI 0.51 to 1.21, p = 0.27) showed a significant difference (**Supplementary Fig. 7**).

``										N	N
		Norepir				henylep				Mean Difference	Mean Difference
	idy or Subgroup	Mean	SD			lean	SD		Weight	IV. Fixed, 95% (
	oorva Singh 2022	7.3	0.06		50	7.3	0.05	50	2.3%	0.00 [-0.02, 0.02	
	en 2022	7.295	0.035			.292	0.036	50	5.5%	0.00 [-0.01, 0.02	
	o 2020	7.31	0.02			7.32	0.02	22	7.6%	-0.01 [-0.02, 0.00]	
	ng 2017	7.3	0.03			7.29	0.02	64	13.4%	0.01 [0.00, 0.02]	
	kandr Am 2021	7.37	0.03			7.38	0.03	25	3.9%	-0.01 [-0.03, 0.01]	
	o 2022	7.31	0.07			7.31	0.06	69	2.3%	0.00 [-0.02, 0.02]	
	sanin 2019	7.31	0.05			7.29	0.06	63	2.8%	0.02 [0.00, 0.04]	
	karan Singh 2022	7.29	0.04			7.28	0.04	30	2.6%	0.01 [-0.01, 0.03]	
	2022	7.33	0.04			7.33	0.03	23	2.7%	0.00 [-0.02, 0.02]	
Mol	hta 2019	7.25	0.1		45	7.29	0.07	45	0.8%	-0.04 [-0.08, -0.00]	· · · · · · · · · · · · · · · · · · ·
Mol	hta 2021	7.27	0.06		43	7.26	0.06	43	1.7%	0.01 [-0.02, 0.04]	
Mol	hta 2022	7.252	0.082		46 7	.251	0.081	48	1.0%	0.00 [-0.03, 0.03]	
Nga	an Kee 2015	7.3	0.04		49	7.3	0.03	52	5.6%	0.00 [-0.01, 0.01]	
Nga	an Kee 2020	7.289	0.049	1 3	33 7	.286	0.048	335	19.7%	0.00 [-0.00, 0.01]	·
	A 2022	7.3	0.05		45	7.27	0.05	45	2.5%	0.03 [0.01, 0.05]	
Sha	arkey 2019	7.24	0.08		56	7.25	0.05	56	1.7%	-0.01 [-0.03, 0.01]	
	ing 2019	7.32	0.02			7.32	0.02	55	19.3%	0.00 [-0.01, 0.01	
	ing 2020	7.307	0.09			.313	0.09	50	0.9%	-0.01 [-0.04, 0.03	
	ou 2022	7.31	0.03			7.31	0.03	25	3.9%	0.00 [-0.02, 0.02]	
2110	ee modele	1.01	0.00				0.00	20	0.070	5.50 [-0.0z, 0.0z]	
Tot	tal (95% CI)			11	43			1150	100.0%	0.00 [-0.00, 0.01]	•
	terogeneity: Chi ² = 27	40 df =	18 (n = 0								
	st for overall effect: Z				- 0470						-0.05 -0.025 0 0.025 0.05
163	st for overall effect. Z	- 1.20 (b	- 0.29)								Favours Norepinephrine Favours Phenylephrine
D \					Disc					Difference	N D!//
B)			oinephr			ylephr				Difference	Mean Difference
	dy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, R	andom, 95% Cl	IV. Random, 95% CI
3.1	.1 Prophylactic infu	ision									
Apo	oorva Singh, 2022	7.3	0.06	50	7.3	0.05	50	4.7%	0.0	00 [-0.02, 0.02]	
Che	en, 2022	7.295	0.035	50	7.292	0.036	50	8.6%		00 [-0.01, 0.02]	
	kandr Am, 2021	7.37	0.03	25	7.38	0.03	25	6.9%		01 [-0.03, 0.01]	
	o, 2022	7.31	0.03	69	7.31	0.06	69	4.6%		00 [-0.02, 0.02]	
				60	7.29	0.06	63	4.0%			
	sanin, 2019	7.31	0.05							.02 [0.00, 0.04]	
	skaran Singh, 2022	7.29	0.04	30	7.28	0.04	30	5.2%		01 [-0.01, 0.03]	
	, 2022	7.33	0.04	25	7.33	0.03	23	5.3%		00 [-0.02, 0.02]	
Nga	an Kee, 2015	7.3	0.04	49	7.3	0.03	52	8.6%	0.0	00 [-0.01, 0.01]	
	ou, 2022	7.31	0.03	25	7.31	0.03	25	6.9%		00 [-0.02, 0.02]	
Sul	btotal (95% CI)			383			387	56.2%	0.0	0 [-0.00, 0.01]	•
Het	terogeneity: Tau ² = 0.	00 ⁻ Chi ² :	= 6 14 d	f = 8 (n	= 0.63	$f^2 = 0\%$					
	st for overall effect: Z				,	,					
100		0.01 ()	0.02)								
3.1	.2 Bolus										
Ch	o. 2020	7.31	0.02	22	7.32	0.02	22	10.2%	-0.0	01 [-0.02, 0.00]	
	hta, 2019	7.25	0.02	45	7.29	0.02	45	2.0%		4 [-0.08, -0.00]	
	hta, 2021	7.27	0.06	43	7.26	0.06	43	3.6%		01 [-0.02, 0.04]	
Mo	hta, 2022	7.252	0.082	46	7.251	0.081	48	2.3%		00 [-0.03, 0.03]	
	i A 2022	7.3	0.05	45	7.27	0.05	45	5.0%		.03 [0.01, 0.05]	
Rai		7.24	0.08	56	7.25	0.05	56	3.8%		01 [-0.03, 0.01]	
Rai Sha	arkey, 2019			FC	7.32	0.02	55	14.7%	0.0	00 [-0.01, 0.01]	
Rai Sha	arkey, 2019 ang, 2019	7.32	0.02	56			50	2.1%	-0.0	01 [-0.04, 0.03]	
Rai Sha Wa			0.02 0.09		7.313	0.09	50				
Rai Sha Wa Wa	ang, 2019	7.32			7.313	0.09	50 364	43.8%		0 [-0.01, 0.01]	
Rai Sha Wa Wa	ang, 2019 ang, 2020 btotal (95% CI)	7.32 7.307	0.09	52 365			364			0 [-0.01, 0.01]	
Rai Sha Wa Wa Sul Het	ang, 2019 ang, 2020 btotal (95% CI) terogeneity: Tau ² = 0.	7.32 7.307 00; Chi ² =	0.09 = 16.84,	52 365			364			0 [-0.01, 0.01]	
Rai Sha Wa Wa Sul Het	ang, 2019 ang, 2020 btotal (95% CI)	7.32 7.307 00; Chi ² =	0.09 = 16.84,	52 365			364			0 [-0.01, 0.01]	
Rai Sha Wa Sul Het Tes	ang, 2019 ang, 2020 btotal (95% CI) terogeneity: Tau ² = 0.	7.32 7.307 00; Chi ² =	0.09 = 16.84,	52 365			364 8%		-0.0	00 [-0.01, 0.01] 00 [-0.00, 0.01]	
Rai Sha Wa Sul Het Tes	ang, 2019 ang, 2020 btotal (95% CI) terogeneity: Tau ² = 0. st for overall effect: Z	7.32 7.307 00; Chi ² = = 0.20 (p	0.09 = 16.84, = 0.84)	52 365 df = 7 (748	p = 0.03	2); /2 = 5	364 8% 751	43.8%	-0.0		

FIGURE 2. Umbilical artery pH. (A) Forest plot for umbilical artery pH. (B) Forest plot for subgroup analysis of umbilical artery pH. CI: confidence interval; SD: standard deviation.

(Δ)		Noreni	nephrine	aroup	Р	honvlor	ohrine ç	roup		Mean Differend	-0	Mean Difference
(~)	Study or Subaroup	Mean	SD			lean	SD		Weight	IV. Fixed, 95		IV. Fixed, 95% Cl
-	Biricik 2020	7.34	0.06			7.31	0.03	40	3.0%	0.03 [0.01, 0.		
	Chen 2022	7.334	0.029			.338	0.031	50	9.5%	-0.00 [-0.02, 0.		
	Dong 2017	7.34	0.02		62	7.3	0.1	64	2.1%	0.04 [0.01, 0.		
	Du 2022	7.34	0.02			7.34	0.04	31	5.3%	0.00 [-0.02, 0.		
	Jaskaran Singh 2022	7.33	0.02			7.31	0.04	30	4.1%	0.02 [0.00, 0.		
	Liu 2022	7.38	0.02			7.38	0.02	23	10.3%	0.00 [-0.01, 0.		
	Mohta 2019	7.29	0.11			7.33	0.02	45	0.8%			
	Mohta 2021	7.31	0.07			7.31	0.06	43	1.7%	0.00 [-0.03, 0.	.00]	
	Mohta 2022	7.303	0.084			.307	0.073	48	1.3%	-0.00 [-0.04, 0.		
	Ngan Kee 2015	7.35	0.084			7.34	0.073	52	13.4%	0.01 [0.00, 0.		
	Ngan Kee 2020	7.338	0.02			.335	0.044	335	27.6%	0.00 [-0.00, 0.		
	Puthenveettil 2019	7.32	0.047			.335	0.476	25	27.6%	0.00 [-0.00, 0.		,
	Rai A 2022	7.32	0.038			7.31	0.476	25 45	3.8%	0.00 [-0.19, 0.		· ·
	Sharkey 2019	7.3	0.04			7.31	0.05	45	2.6%			
	Theodoraki 2020	7.35	0.07			7.32	0.05	41	2.0%	-0.01 [-0.03, 0.		
	Tiwari 2022	7.39	1.19			7.32	0.93	63	0.0%	0.03 [0.01, 0.		
	Vallejo 2017	7.25	0.12			7.28	0.93	5	0.0%	-0.03 [-0.14, 0.		
	Wang 2020	7.25	0.12			7.36	0.08	50	1.2%	0.01 [-0.02, 0.		
	Zhou 2022	7.37	0.02		25	7.36	0.02	25	10.7%	0.01 [-0.00, 0.	.02]	
	Total (95% CI)			10	68			1071	100.0%	0.01 [0.00, 0.	01]	♦
	Heterogeneity: Chi2 = 33	3.29, df =	18 (p = 0	.02); <i>P</i>	= 46%						-	0.1 -0.05 0 0.05 0.1
	Test for overall effect: Z											Favours Norepinephrine Favours Phenylephrine
(B)			pinephri			nylephi				Difference		Mean Difference
·-/.	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. R	andom, 95% Cl		IV. Random, 95% CI
	3.2.1 Prophylactic info	usion										
	Biricik, 2020	7.34	0.06	40	7.31	0.03	40	6.4%	0	.03 [0.01, 0.05]		
	Chen, 2022	7.334	0.029	50	7.338	0.031	50	11.5%	-0.	00 [-0.02, 0.01]		
	Du, 2022	7.34	0.02	31	7.34	0.04	31	8.8%	0.	00 [-0.02, 0.02]		
	Jaskaran Singh, 2022	7.33	0.03	30	7.31	0.04	30	7.7%	0	.02 [0.00, 0.04]		
	Liu, 2022	7.38	0.02	25	7.38	0.02	23	11.8%	0.0	00 [-0.01, 0.01]		
	Ngan Kee, 2015	7.35	0.02	49	7.34	0.03	52	12.9%	0	.01 [0.00, 0.02]		
	Theodoraki, 2020	7.35	0.03	41	7.32	0.07	41	5.4%		.03 [0.01, 0.05]		
	Vallejo, 2017	7.25	0.12	7	7.28	0.08	5	0.3%		03 [-0.14, 0.08]	←	
	Zhou, 2022	7.37	0.02	25	7.36	0.02	25	12.0%		01 [-0.00, 0.02]		
	Subtotal (95% CI)	1101	0101	298	1100	0.01	297	76.9%		01 [0.00, 0.02]		◆
	Heterogeneity: Tau ² = 0			df = 8 (p = 0.03	3); <i>I</i> ² = 5	3%					
	Test for overall effect: 2	c = 2.4 (p	= 0.02)									
	3.2.2 Bolus											
	Mohta, 2019	7.29	0.11	45	7.33	0.08	45	2.3%		4 [-0.08, -0.00]		
	Mohta, 2021	7.31	0.07	43	7.31	0.06	43	4.2%		00 [-0.03, 0.03]		
	Mohta, 2022	7.303	0.084	46	7.307	0.073	48	3.4%	-0.	00 [-0.04, 0.03]		
	Puthenveettil, 2019	7.32	0.038	25	7.318	0.476	25	0.1%	0.	00 [-0.19, 0.19]	←	· · · ·
	Rai A 2022	7.32	0.04	45	7.31	0.05	45	7.3%		01 [-0.01, 0.03]		+
	Sharkey, 2019	7.3	0.07	56	7.31	0.05	56	5.7%	-0.0	01 [-0.03, 0.01]		
	Tiwari, 2022	7.39	1.19	63	7.32	0.93	63	0.0%		07 [-0.30, 0.44]	←	
	Subtotal (95% CI)			323		0.00	325	23.1%		00 [-0.01, 0.01]		*
	Heterogeneity: Tau ² = 0	00: Chi2	= 5.75. dt	= 6 (n	= 0.45)	r /2 = 0.9	6					
	Test for overall effect: 2			0.05	0.10,	., .,	•					
	Total (95% CI)			621			622	100.0%	0.0	01 [-0.00, 0.01]		•
	Heterogeneity: Tau ² = 0	0.00 [,] Chi2	= 25.40		(n = 0)	04)· P=						
	Test for overall effect: 2				. ₁ p = 0.	• 9, r · =	. 1 70				-0.1	-0.05 0 0.05 0.1
	Test for subgroup differ				(p = 0.	09); <i>I</i> ² =	65.0%					Favours Norepinephrine Favours Phenylephrine

FIGURE 3. Umbilical venous pH. (A) Forest plot for umbilical venous pH. (B) Forest plot for subgroup analysis of umbilical venous pH. CI: confidence interval; SD: standard deviation.

Study or Subgroup	Mean	ephrine g SD	Total	Mean	phrine gi SD		Weight	Mean Difference IV. Random, 95% CI	Mean Difference IV, Random, 95% Cl
Apoorva Singh 2022	29.5	12.3	50	29.4	16.5	50	1.9%	0.10 [-5.60, 5.80]	
Chen 2022	18.36	5.123	50	29.4 19.74	4.79	50	7.1%	-1.38 [-3.32, 0.56]	
Cho 2020	18.21	2.96	22	19.63	2.23	22	8.1%	-1.42 [-2.97, 0.13]	
Dong 2017	17.33	5.93	62	19.05	5.19	64	7.1%	1.33 [-0.62, 3.28]	
Eskandr Am 2021	25.94	3.07	25	27.47	2.15	25	8.3%	-1.53 [-3.00, -0.06]	
Guo 2022	23.94	7.5	69	23.25	2.15	69	6.3%	0.00 [-2.27, 2.27]	
Hasanin 2019	26.33	2.96	60	23.25	9.63	63	5.8%	5.33 [2.84, 7.82]	
Liu 2022	19.2	3.48	25	17.33	3.19	23	7.2%	1.87 [-0.02, 3.76]	
Mohta 2019	19.2	3.40 14.4	45	20.4	23.3	45	1.1%	-2.90 [-10.90, 5.10]	
Mohta 2019	28.1	14.4	43	20.4	7.2	43	2.1%	5.20 [-0.18, 10.58]	
Mohta 2021	20.1	6.7	43	22.9	7.5	43	5.0%	0.30 [-2.57, 3.17]	
Ngan Kee 2015	21.4	6.75	40	13.67	6.75	40 52	5.5%		
Ngan Kee 2015	16.5	3.75	333	16.5	5.25	335	10.2%	1.63 [-1.00, 4.26] 0.00 [-0.69, 0.69]	<u> </u>
Rai A 2022	16.49	7.62	333 45	15.45	7.63	335 45	4.5%	1.04 [-2.11, 4.19]	
Sharkey 2019	16.49	7.62	45 56	15.45	7.63	45 56	4.5%	0.00 [-2.96, 2.96]	
Wang 2019	14.5	5.8	56	13.5	4.4	55	4.8%	1.00 [-0.91, 2.96]	
Wang 2019 Wang 2020	22.67	30.37	52	13.5	4.4 14.81	50	0.8%	7.67 [-1.55, 16.89]	
Zhou 2022	17.33	4.3	25	19.54	3.03	25	6.8%	-2.21 [-4.27, -0.15]	
21100 2022	17.55	4.5	20	15.54	3.05	25	0.076	-2.21 [-4.27, -0.13]	
Total (95% CI)			1113			1120	100.0%	0.41 [-0.46, 1.29]	+
Heterogeneity: Tau ² =	1.82 Chi2	= 46 47 d	f = 17 (n	= 0.0001)	P = 63%				-4 -2 0 2 4
Test for overall effect	: Z = 0.93 (o = 0.35)							Favours Norepinephrine Favours Phenylephr
Test for overall effect	Z = 0.93 (o = 0.35) ephrine g			ephrine g			Mean Difference	Mean Difference
Test for overall effect Study or Subgroup	Z = 0.93 (Norepir Mean	ephrine g	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	
Test for overall effect Study or Subgroup Biricik 2020	Z = 0.93 (Norepir <u>Mean</u> 24.2	ephrine g 5D 7.48	Total 40	Mean 28.4	SD 5.3	Total 40	6.1%	IV. Random. 95% Cl -4.20 [-7.04, -1.36]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022	Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7	ephrine g 5D 7.48 8.53	Total 40 50	Mean 28.4 28.49	5.3 8.09	<u>Total</u> 40 50	6.1% 5.5%	IV, Random, 95% Cl -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017	. Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 29.67	ephrine g SD 7.48 8.53 5.19	Total 40 50 62	Mean 28.4 28.49 28	5.3 8.09 4.44	Total 40 50 64	6.1% 5.5% 7.8%	IV. Random, 95% Cl -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022	.: Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 29.67 26.667	ephrine g SD 7.48 8.53 5.19 2.963	Total 40 50 62 31	Mean 28.4 28.49 28 24.833	5.3 8.09 4.44 4.815	Total 40 50 64 31	6.1% 5.5% 7.8% 7.3%	IV. Random. 95% Cl -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022	.: Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 29.67 26.667 28.8	ephrine g SD 7.48 8.53 5.19 2.963 4.5	Total 40 50 62 31 25	Mean 28.4 28.49 28 24.833 27.7	SD 5.3 8.09 4.44 4.815 5.2	Total 40 50 64 31 23	6.1% 5.5% 7.8% 7.3% 6.2%	<u>IV. Random. 95% Cl</u> -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019	. Z = 0.93 (Norepir Mean 24.2 27.7 29.67 26.667 28.8 33.4	ephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1	Total 40 50 62 31 25 45	Mean 28.4 28.49 28 24.833 27.7 26.4	SD 5.3 8.09 4.44 4.815 5.2 28.2	Total 40 50 64 31 23 45	6.1% 5.5% 7.8% 7.3% 6.2% 0.8%	IV. Random. 95% Cl -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021	. Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 29.67 26.667 28.8 33.4 39	ephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4	Total 40 50 62 31 25 45 45 43	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8	Total 40 50 64 31 23 45 43	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1%	<u>IV. Random. 95% Ci</u> -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16] 9.50 [3.79, 15.21]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2021 Mohta 2021 Mohta 2022	E Z = 0.93 (Norepir Mean 24.2 27.7 29.67 26.667 28.8 33.4 39 33	ephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5	Total 40 50 62 31 25 45 43 43 46	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1	Total 40 50 64 31 23 45 43 43 48	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1%	<u>IV. Random. 95% Cl</u> -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28]	Mean Difference
Test for overall effect <u>Study or Subgroup</u> Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Mohta 2022 Mohta 2022 Ngan Kee 2015	. Z = 0.93 (Norepir Mean 24.2 27.7 29.67 26.667 28.8 33.4 39 33 26.67	ephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19	Total 40 50 62 31 25 45 45 43 46 49	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7	Total 40 50 64 31 23 45 43 45 43 48 52	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6%	<u>IV. Random. 95% Cl</u> -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77]	Mean Difference
Test for overall effect Study or Subgroup Bircik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Mohta 2022 Ngan Kee 2015 Ngan Kee 2020	: Z = 0.93 (Norepir Mean 24.2 29.67 26.667 28.8 33.4 39 33 26.67 24.75	ephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6	Total 40 50 62 31 25 45 43 46 49 333	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6	Total 40 50 64 31 23 45 43 48 52 335	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7%	IV. Random. 95% Ci -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 7.00 [-6.16, 2.016] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.91, 0.91]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Mohta 2021 Ngan Kee 2015 Ngan Kee 2020 Puthenveetti 2019	: Z = 0.93 (Norepir Mean 24.2 27.7 29.67 26.667 28.8 33.4 39 33 26.67 24.75 28.18	p = 0.35) ephrine g <u>SD</u> 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421	Total 40 50 62 31 25 43 46 49 333 25	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879	Total 40 50 64 31 23 45 43 45 43 48 52 335 25	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 4.3%	V. Random. 95% Ci 4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 7.00 [-6.16, 2.0.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.91, 0.91] 2.51 [-1.85, 6.86]	Mean Difference
Test for overall effect Study or Subgroup Stircik 2020 Chen 2022 Dong 2017 Du 2022 Mohta 2019 Mohta 2019 Mohta 2021 Mohta 2022 Ngan Kee 2015 Ngan Kee 2020 Puthenveetili 2019 Rai A 2022	: Z = 0.93 (Norepir Mean 24.2 27.7 29.67 26.667 28.8 33 33 26.67 24.75 28.18 25.53	p = 0.35) rephrine g 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21	Total 40 50 62 31 25 43 46 49 333 25 45	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 25.672 23.41	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43	Total 40 50 64 31 23 45 43 45 43 48 52 335 25 45	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 4.3% 5.6%	IV. Random. 95% Ci -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.71, 2.77] 0.00 [-1.12, 5.36]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2027 Du 2022 Liu 2022 Mohta 2021 Mohta 2021 Mohta 2021 Ngan Kee 2015 Ngan Kee 2020 Puthenveetii 2019 Rai A 2022 Sharkey 2019	: Z = 0.93 (Norepir Mean 24.2 27.7 26.667 28.8 33.4 39 33 26.67 24.75 28.18 25.53 28.18 25.53 24	p = 0.35) rephrine g 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7	Total 40 50 62 31 25 45 43 46 49 333 25 45 56	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 23.41 25	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8	Total 40 50 64 31 23 45 43 45 335 25 45 56	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 4.3% 5.6% 6.2%	IV. Random. 95% CI -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.00 [-6.16, 2.0.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.310, 0.91] 2.51 [-1.85, 6.86] 2.12 [-1.12, 5.36] -1.00 [-3.78, 1.78]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2019 Mohta 2021 Ngan Kee 2015 Ngan Kee 2015 Ngan Kee 2015 Sharkey 2019 Theodoraki 2020	: Z = 0.93 (Norepir Mean 24.2 27.7 26.667 28.8 33.4 39 33 26.67 24.75 28.18 25.53 24.8 26.4	p = 0.35) ephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7.21 7.21 7 5.333	Total 40 50 62 31 25 45 43 46 49 333 25 45 56 41	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.672 24.75 25.672 23.41 25 24.625	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8 6.388	Total 40 50 64 31 23 45 43 45 335 25 45 56 41	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 4.3% 5.6% 6.2% 6.5%	UV. Random. 95% CI -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 2.02] 1.03 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-3.91, 0.91] 2.51 [-1.85, 6.86] 2.12 [-1.12, 5.36] -1.00 [-3.78, 1.78] 1.77 [-0.77, 4.32]	Mean Difference
Test for overall effect Study or Subgroup Bircik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Mohta 2021 Mohta 2022 Ngan Kee 2015 Ngan Kee 2020 Puthenveettil 2019 Rai A 2022 Sharkey 2019 Theodoraki 2020 Theodoraki 2020	: Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 26.667 28.8 33.4 39 33 26.67 24.75 28.18 25.53 28.18 25.53 24 26.4	p = 0.35) rephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7.21 7.33 2.89	Total 40 50 62 31 25 45 43 46 49 3335 45 56 41 63	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 23.67 24.75 25.672 23.67 24.625 28.3	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8 6.388 2.23	Total 40 50 64 31 23 45 43 52 335 25 45 56 41 63	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 4.3% 6.2% 6.5% 8.7%	IV. Random. 95% CI -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-5.16, 20.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.91, 0.91] 2.51 [-1.85, 6.86] -1.00 [-3.78, 1.78] 1.77 [-0.77, 4.32] -2.90 [-3.80, -2.00]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Ngan Kee 2015 Ngan Kee 2020 Puthenveetil 2019 Rai A 2022 Sharkey 2019 Theodoraki 2020 Tiwari 2022 Vallejo 2017	: Z = 0.93 (Norepir Mean 24.2 27.7 26.667 28.8 33.4 33 26.67 24.75 28.18 25.53 24 26.4 25.43	p = 0.35) pephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7.23 3.33 2.89 2.61	Total 40 50 62 31 25 43 46 49 333 25 45 56 41 63 43	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 23.41 25 24.625 24.625 28.3 50.67	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8 6.388 2.23 11.45	Total 40 50 64 31 23 45 25 45 56 41 63 38	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 7.6% 8.7% 4.3% 5.6% 6.2% 6.5% 8.7% 2.2%	IV. Random. 95% Ci -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.00 [-6.16, 2.0.16] 9.50 [3.79, 15.21] -0.00 [-0.77, 2.77] 0.00 [-0.31, 0.91] 2.51 [-1.85, 6.86] 2.12 [-1.12, 5.36] -1.00 [-3.78, 1.78] -1.77 [-0.77, 4.32] -2.90 [-3.80, -2.00] 7.66 [0.50, 14.82]	Mean Difference
Test for overall effect Study or Subgroup Bricik 2020 Chen 2022 Dong 2017 Du 2022 Mohta 2019 Mohta 2021 Mohta 2021 Mohta 2022 Mohta 2022 Ngan Kee 2015 Ngan Kee 2020 Puthenveetiil 2019 Rai A 2022 Sharkey 2019 Theodoraki 2020 Tiwari 2022 Vallejo 2017 Wang 2020	: Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 29.67 26.667 28.18 33.4 33 26.67 24.75 28.18 25.53 24 25.53 24 25.4 58.33 27.07	ephrine g 50 = 0.35) 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7.21 7.21 7.23 2.89 20.61 18.52	Total 40 50 62 31 25 43 46 49 333 25 45 56 41 63 43 52	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 23.41 25 24.625 24.625 28.3 50.67 27.37	SD 5.3 8.09 4.41 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8 6.388 21.45 20.74	Total 40 50 64 31 23 45 43 45 335 25 45 56 41 63 38 50	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 6.2% 6.5% 8.7% 2.2%	IV. Random. 95% CI -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.91, 0.91] 2.51 [-1.85, 6.86] -1.00 [-3.78, 1.78] 1.77 [-0.77, 4.32] -2.90 [-3.80, -2.00] 7.66 [0.50, 14.82] -0.30 [-7.47, 4.73]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Mohta 2021 Mohta 2022 Ngan Kee 2015 Ngan Kee 2020 Puthenveetiil 2019 Rai A 2022 Sharkey 2019 Theodoraki 2020 Tiwari 2022 Vallejo 2017 Wang 2020	: Z = 0.93 (Norepir Mean 24.2 27.7 26.667 28.8 33.4 33 26.67 24.75 28.18 25.53 24 26.4 25.43	p = 0.35) pephrine g SD 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7.23 3.33 2.89 2.61	Total 40 50 62 31 25 43 46 49 333 25 45 56 41 63 43	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 23.41 25 24.625 24.625 28.3 50.67	SD 5.3 8.09 4.44 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8 6.388 2.23 11.45	Total 40 50 64 31 23 45 25 45 56 41 63 38	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 7.6% 8.7% 4.3% 5.6% 6.2% 6.5% 8.7% 2.2%	IV. Random. 95% Ci -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.00 [-6.16, 2.0.16] 9.50 [3.79, 15.21] -0.00 [-0.77, 2.77] 0.00 [-0.31, 0.91] 2.51 [-1.85, 6.86] 2.12 [-1.12, 5.36] -1.00 [-3.78, 1.78] -1.77 [-0.77, 4.32] -2.90 [-3.80, -2.00] 7.66 [0.50, 14.82]	Mean Difference
Test for overall effect Study or Subgroup Biricik 2020 Chen 2022 Dong 2017 Du 2022 Liu 2022 Mohta 2019 Mohta 2021 Mohta 2021 Ngan Kee 2015 Ngan Kee 2020 Puthenveetli 2019 Rai A 2022 Sharkey 2019 Theodoraki 2020 Tiwari 2022 Vallejo 2017	: Z = 0.93 (Norepir <u>Mean</u> 24.2 27.7 29.67 26.667 28.18 33.4 33 26.67 24.75 28.18 25.53 24 25.53 24 25.4 58.33 27.07	ephrine g 50 = 0.35) 7.48 8.53 5.19 2.963 4.5 35.1 16.4 9.5 5.19 6 9.421 7.21 7.21 7.21 7.23 2.89 20.61 18.52	Total 40 50 62 31 25 43 46 49 333 25 45 56 41 63 43 52	Mean 28.4 28.49 28 24.833 27.7 26.4 29.5 33.3 25.67 24.75 25.672 23.41 25 24.625 24.625 28.3 50.67 27.37	SD 5.3 8.09 4.41 4.815 5.2 28.2 9.8 8.1 3.7 6 5.879 8.43 8 6.388 21.45 20.74	Total 40 50 64 31 23 45 43 48 52 335 25 56 41 63 38 50 25	6.1% 5.5% 7.8% 7.3% 6.2% 0.8% 3.1% 5.1% 7.6% 8.7% 6.2% 6.5% 8.7% 2.2%	IV. Random. 95% CI -4.20 [-7.04, -1.36] -0.79 [-4.05, 2.47] 1.67 [-0.02, 3.36] 1.83 [-0.16, 3.82] 1.10 [-1.66, 3.86] 7.00 [-6.16, 20.16] 9.50 [3.79, 15.21] -0.30 [-3.88, 3.28] 1.00 [-0.77, 2.77] 0.00 [-0.91, 0.91] 2.51 [-1.85, 6.86] -1.00 [-3.78, 1.78] 1.77 [-0.77, 4.32] -2.90 [-3.80, -2.00] 7.66 [0.50, 14.82] -0.30 [-7.47, 4.73]	Mean Difference

FIGURE 4. Umbilical cord PaO₂. (A) Forest plot for umbilical artery PaO₂. (B) Forest plot for umbilical venous PaO₂. CI: confidence interval; SD: standard deviation.

 Nean Difference

 Total
 Weight
 IV. Fixed. 95% CI

 50
 3.8%
 1.60 (-1.28, 4.48)

 50
 5.9%
 0.04 [-2.28, 2.36]

 50
 3.8%
 1.80 (-1.28, 4.48)

 50
 5.9%
 0.04 [-2.28, 2.36]

 52
 6.7%
 2.12 (-0.05, 4.29)

 64
 7.3%
 -0.33 [2.42, 1.76]

 63
 4.2%
 0.00 [-2.76, 2.76]

 63
 4.5%
 -2.00 [-4.66, 0.66]

 63
 4.5%
 -2.00 [-4.76, 2.76]

 43
 2.0%
 -0.70 [-4.74, 3.34]

 48
 1.6%
 2.80 [-1.61, 7.21]

 52
 5.2%
 0.00 [-1.20, 1.20]

 53
 52.2%
 0.00 [-1.20, 1.20]

 54
 1.3%
 0.34 [-4.64, 5.22]

 55
 12.7%
 0.00 [-1.48, 1.68]

 50
 1.1%
 -1.33 [-6.64, 4.00]

 55
 12.7%
 0.10 [-1.48, 1.68]

 50
 1.1%
 -1.33 [-6.64, 4.00]

 25
 1.2%
 0.10 [-1.48, 1.68]

 50
 <td Norepinephrine phrine arour Mean Difference Mean Differenc Study or Subgroup Apoorva Singh 2022 Chen 2022 Eskandr Am 2021 Guo 2002 Eskandr Am 2021 Guo 2002 Hasanin 2019 Liu 2022 Mohta 2021 Mohta 2021 Mohta 2021 Mohta 2021 Ngan Kee 2020 Sharkey 2019 Wang 2019 Wang 2020 Mear SD Total Mean SD IV. F ed. 95% CI 40.3 48.7 51.35 50 39.6 45 47 51.4 53.7 46.1 51.4 51.3 47.25 47.97 56 50.9 7.3 6.38 3.96 6.67 3.4 9 8 6.4 11.8 9.7 10.3 5.93 7.5 10.99 11 4.1 50 50 38.7 48.66 49.23 50.33 38.5 45 49 48.6 52.2 46.8 48.6 52.2 46.8 48.6 52 47.25 47.63 7.4 5.39 3.37 5.19 2.94 7.5 7 6.6 10.6 9.4 11.5 5.93 8.25 12.6 22 62 25 69 60 25 45 43 46 49 333 45 56 56 52 25 9 4.4 12.6 4.66 59 50.8 Wang 2020 Zhou 2022 49.67 51.14 14.81 51 51.02 5.12 1120 100.0% 0.22 [-0.34, 0.79] Total (95% CI) 1113 Heterogeneity: $Chi^2 = 15.42$, df = 17 (p = 0.57); $l^2 = 0\%$ Test for overall effect: Z = 0.77 (p = 0.44) + 4 -2 Favours Norepinephrine ò 2 (B) Study or Sub Birkick 2020 Dong 2017 Do 2022 Liv 2022 Liv 2022 Mohta 2019 Mohta 2019 Mohta 2019 Mohta 2021 Mohta 2020 Puthervettil 2010 Rair A 2022 Sharkey 2019 Theodoraki 2020 Tivari 2029 Theodoraki 2020 Tivari 2022 Sharkey 2019 Theodoraki 2020 Tivari 2022 Total (95% C^{*} Favours Phenylephrine Mean Difference <u>IV, Random, 95%</u> CI, 0.00 [-1.53, 1.53] 1.28 [-0.71, 3.27] -1.00 [-2.29, 0.29] -1.60 [-4.46, 1.26] 0.00 [-1.63, 3.83] -2.60 [-6.05, 0.85] 2.60 [-1.77, 6.37] 0.06 [-2.41, 1.09] 0.00 [-1.02, 1.02] 2.84 [-5.18, 0.48] -1.17 [-5.49, 3.16] 1.00 [-1.78, 3.78] -0.58 [-3.28, 2.12] 3.70 [2.61, 4.78, 3.78] -0.58 [-3.28, 0.04] -1.33 [-5.79, 3.13] -1.51 [-3.86, 0.84] -1.41 [-3.78] Mean Differenc an Differenc Mean 39.8 42.67 42.67 44.4 41.1 45 SD 3.48 4.81 3.7 5.9 3 SD Weight 7.3% 6.7% 7.7% 5.3% 7.2% 3.2% 4.6% 4.6% 4.2% 7.0% 8.0% 6.1% 3.6% 5.5% 0.5% 6.1% IV, Random, 95% CI Total 40 50 62 31 25 45 43 46 49 333 25 56 56 41 63 43 52 25 Mean 39.8 41.39 43.67 46 41.1 45.9 39.1 36.3 41.33 40.5 46.7 41.07 47 44.83 42.8 50.83 43 Total 40 50 64 31 23 45 43 45 43 48 52 335 25 56 41 63 38 50 25 3.5 5.33 3.7 5.59 2.8 7.2 7.9 8.9 5.19 6.75 1.172 10.05 14.5 8.4 9.7 3.7 6.75 5.864 10.86 8 45 36.5 38.9 40.67 40.5 43.864 39.9 48 48 44.25 46.5 25 41.67 8 6.85 2.51 11.11 11.85 4.57 7 5.56 3.61 43.33 11.11 3.88 39.81 41.32 Total (95% CI) 1074 1074 100.0% -0.34 [-1.41, 0.73] Heterogeneity: Tau² = 3.46; Chi² = 74.16, df = 17 (p < 0.00001); l^2 = 77% Test for overall effect: Z = 0.62 (p = 0.54) -4 -2 + 4 vlenhrine Fav

FIGURE 5. Umbilical cord PaCO₂. (A) Forest plot for umbilical artery PaCO₂. (B) Forest plot for umbilical venous PaCO₂. CI: confidence interval; SD: standard deviation.




FIGURE 6. The incidence of hypotension after vasopressor-use. (A) Forest plot for maternal hypotension. (B) Forest plot for subgroup analysis of maternal hypotension. CI: confidence interval; SD: standard deviation.




FIGURE 7. Forest plot for maternal bradycardia. CI: confidence interval.

3.5.3 The incidence of reactive hypertension

13 studies involving 1304 parturient women reported reactive hypertension after norepinephrine or phenylephrine administration. According to the meta-analysis, reactive hypertension incidence was not significantly different between these 13 studies, with a RR (95% CI) of 0.53 (0.39 to 0.72; p <

0.001) (Fig. 9). There was no subgroup effect related to drug administration mode (p = 0.89). Neither the prophylactic infusion group (RR 1.86, 95% CI 1.30 to 2.67, p < 0.001) or the bolus group (RR 1.67, 95% CI 0.38 to 7.29, p = 0.50) showed a significant difference (**Supplementary Fig. 8**).

	Norepinephrine	group	Phenylephrine	group		Risk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fi	ked. 95% Cl		
Biricik 2020	10	40	8	40	3.8%	1.25 [0.55, 2.84]			· · · ·		
Chen 2022	1	50	2	50	1.0%	0.50 [0.05, 5.34]	←				
Cho 2020	2	22	2	22	1.0%	1.00 [0.15, 6.48]		-			
Dong 2017	2	62	3	64	1.4%	0.69 [0.12, 3.98]	-	•			
Du 2022	9	31	7	31	3.3%	1.29 [0.55, 3.02]					
Eskandr Am 2021	0	25	3	25	1.7%	0.14 [0.01, 2.63]	+	•			
Goel 2021	7	100	11	100	5.2%	0.64 [0.26, 1.57]					
Guo 2022	7	69	6	69	2.9%	1.17 [0.41, 3.29]		-		-	
Hasanin 2019	12	60	5	63	2.3%	2.52 [0.94, 6.72]			-		
Jaskaran Singh 2022	1	30	0	30	0.2%	3.00 [0.13, 70.83]					
Liu 2022	6	26	2	26	1.0%	3.00 [0.67, 13.51]					
Ngan Kee 2015	3	49	2	52	0.9%	1.59 [0.28, 9.12]			_		
Ngan Kee 2020	91	332	79	332	37.6%	1.15 [0.89, 1.49]			┼╋╌		
Puthenveettil 2019	2	25	2	25	1.0%	1.00 [0.15, 6.55]		-			
Sharkey 2019	16	56	22	56	10.5%	0.73 [0.43, 1.23]					
Theodoraki 2020	2	41	3	41	1.4%	0.67 [0.12, 3.78]	_				
Tiwari 2022	5	63	5	63	2.4%	1.00 [0.30, 3.29]				-	
Vallejo 2017	29	43	34	38	17.2%	0.75 [0.60, 0.95]			-		
Wang 2019	3	56	4	55	1.9%	0.74 [0.17, 3.14]					
Wang 2020	2	52	5	50	2.4%	0.38 [0.08, 1.89]	+				
Zhou 2022	1	25	2	25	1.0%	0.50 [0.05, 5.17]	+				
Total (95% CI)		1257		1257	100.0%	1.00 [0.85, 1.18]			•		
Total events	211		207								
Heterogeneity: Chi ² = 20		4); <i>I</i> ² = 2%					0.1	0.2 0.5	1 2	5	10
Test for overall effect: Z	= 0.03 (p = 0.97)							Favours Norepinephrine	Favours Phen	/lephrine	

FIGURE 8. Forest plot for maternal nausea or vomiting. CI: confidence interval.

	Norepinephrine	group	Phenylephrin	e group		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
Chen 2022	6	50	13	50	13.9%	0.46 [0.19, 1.12]	
Dong 2017	2	62	3	64	3.2%	0.69 [0.12, 3.98]	
Du 2022	10	31	17	31	18.2%	0.59 [0.32, 1.07]	
Goel 2021	3	100	4	100	4.3%	0.75 [0.17, 3.27]	
Guo 2022	3	69	2	69	2.1%	1.50 [0.26, 8.70]	
Hasanin 2019	7	60	15	63	15.7%	0.49 [0.21, 1.12]	
Jaskaran Singh 2022	1	30	0	30	0.5%	3.00 [0.13, 70.83]	
Liu 2022	0	26	1	26	1.6%	0.33 [0.01, 7.82]	· · · · · · · · · · · · · · · · · · ·
Mohta 2019	2	45	1	45	1.1%	2.00 [0.19, 21.28]	
Ngan Kee 2015	4	49	9	52	9.4%	0.47 [0.16, 1.43]	
Rai A 2022	2	45	13	45	13.9%	0.15 [0.04, 0.64]	
Sharkey 2019	6	56	6	56	6.4%	1.00 [0.34, 2.91]	
Zhou 2022	2	25	9	25	9.6%	0.22 [0.05, 0.93]	
Total (95% CI)		648		656	100.0%	0.53 [0.39, 0.72]	•
Total events	48		93				
Heterogeneity: Chi ² = 10	.04, df = 12 (p = 0.6	1); <i>I</i> ² = 0%					0.01 0.1 1 10 100
Test for overall effect: Z	= 3.96 (p < 0.0001)					Favours Norepinephrine Favours Phenylephrine

FIGURE 9. Forest plot for maternal reactive hypertension. CI: confidence interval.

4. Discussion

In this meta-analysis, norepinephrine did not significantly differ from phenylephrine for maternal hypotension after spinal anesthesia in umbilical cord blood acid-base status and AP-GAR scores at 1 minute and 5 minutes. Norepinephrine may also be effective in treating hypotension and exhibit fewer side effects, such as bradycardia and reactive hypertension.

Umbilical blood acid-base status and Apgar scores at 1 minute and 5 minutes for neonates were not statistically different. Despite the importance of maternal hypotension for a fetus, it has not been extensively studied. Spinal hypotension during cesarean delivery has been reported to affect neonatal acid-base balance [41, 42], with neonatal acid-base status serving as a surrogate marker of neonatal well-being. For this meta-analysis, the primary outcome was umbilical artery pH, which is the most commonly used measurement of acidbase imbalances. Based on a systematic review involving 481,753 neonates with known umbilical cord blood gases, a low arterial pH is strongly associated with long-term adverse outcomes [43]. However, there is a lack of clarity about the precise pH threshold for adverse neonatal outcomes with some studies suggesting a pH range of 7.26-7.30 is optimal for the lowest risk of adverse outcomes [44]. Norepinephrine and phenylephrine groups in this meta-analysis had mean umbilical

artery pH and mean umbilical venous pH exceeding 7.2 and approaching the ideal pH range. No significant differences were found in umbilical artery pH. While umbilical venous pH was significantly different between both groups, but not clinically relevant. Also, both groups did not differ significantly on other indicators of neonatal umbilical cord blood gas analysis, including PaO₂, PaCO₂ and BE. Therefore, norepinephrine dose is claimed to not increase neonatal acidosis incidence when used to prevent or treat maternal hypotension after spinal anesthesia compared to phenylephrine.

Due to the ongoing controversy regarding the use of vasopressors in a preventive or therapeutic capacity, a prespecified subgroup analysis of a prophylactic infusion or bolus of norepinephrine or phenylephrine was performed. In obstetric populations undergoing spinal anesthesia, prophylactic vasopressors are generally recommended by the international consensus statements [5]. When phenylephrine was administered prophylactically, a low maternal hypotension incidence was reported compared to a single bolus for treatment [45]. However, the prophylactic administration of phenylephrine is considered too aggressive by some, potentially causing reactive hypertension and bradycardia [46]. In this meta-analysis, a significant difference was not observed between subgroups for umbilical artery pH and maternal hypotension and maternal bradycardia, nausea, vomiting and reactive hypertension. This finding aligns with Heesen's 2014 meta-analysis, despite their smaller sample size [45]. Although our meta-analysis incorporates a large number of trials, the bolus group for maternal hypotension in the subgroup analysis only includes 2 studies, introducing some heterogeneity. Consequently, without conclusive evidence, prophylactic treatment is preferred, as delaying prophylactic vasopressor infusion may compromise its effectiveness in reducing hypotension incidence. Moreover, prophylactic continuous infusion combined with rescue bolus dosing maintains hemodynamics more effectively than rescue dosing alone [47].

Our investigation demonstrates that norepinephrine has a comparable effect on hypotension after spinal anesthesia to phenylephrine, particularly concerning maternal circulation, confirming earlier studies [30, 35, 40]. During cesarean section anesthesia, it is crucial to consider the adverse effects of drugs on the newborn and to ensure maternal circulation stability. This study assessed short-term outcomes, specifically umbilical cord blood gas analysis and APGAR scores. The long-term impact of various vasoactive drugs on neonatal prognosis remains uncertain. For instance, the establishment of early fetal gut flora might be influenced by altered placental blood supply [48]. Research focusing on the fetal implications of anesthetic management of cesarean sections is essential in the future.

In this review, maternal and neonatal outcomes following cesarean sections are comprehensively evaluated. Furthermore, eligibility criteria, data extraction, and outcome evaluation were all conducted in duplicate, demonstrating high inter-rater agreement. To adjust for potential confounders, prespecified subgroup analyses and sensitivity analyses were conducted. In addition, this review included the largest number of RCTs on this subject, achieving optimal information size and allowing for more reliable conclusions. Lastly, the I^2 statistic revealed no significant statistical heterogeneity.

Nevertheless, this meta-analysis has some limitations. We included 26 studies involving various scenarios, including healthy singleton pregnancies, parturient women with preeclampsia, fetal compromise, and healthy twin pregnancies. As a result of limited relevant data, certain critical variables, such as norepinephrine or phenylephrine concentration, prophylactic infusion rate, single bolus dose, and norepinephrine and phenylephrine equivalent dose ratio, may contribute to clinical heterogeneity across trials. Parturient women's CO and stroke volume (SV), which are more accurate hemodynamic indicators, were not evaluated. The effect of fluid administration on maternal circulatory stability was also not considered. Currently, circulation monitoring for cesarean sections is constrained. Cesarean section anesthesia quality and safety may be enhanced by incorporating non-invasive cardiac monitoring or real-time ultrasonic dynamic monitoring. Lastly, no long-term outcomes for newborns were assessed in our analysis due to the lack of relevant indicators in the included trials. A key evaluation metric remains improving perioperative safety and accelerating postoperative recovery.

5. Conclusion

This meta-analysis comprehensively assessed norepinephrine's efficacy in managing maternal hypotension during cesarean section under spinal anesthesia, focusing on neonatal acidemia and maternal hypotension correction. Comparing perioperative norepinephrine with phenylephrine in 2984 patients, we found no evidence of fetal acidosis associated with norepinephrine administration for maternal hypotension. Norepinephrine may also be more effective than phenylephrine in managing maternal hypotension and providing excellent maternal hemodynamic stability. However, the potential risk of norepinephrine-induced maternal reactive hypertension should not be ignored. Findings were specific to women without comorbidities. Therefore, it is crucial to evaluate the health conditions of both the mother and the fetus before selecting between the two drugs. Further studies evaluating the safety of norepinephrine and phenylephrine in managing post-anesthesia hypotension in women undergoing cesarean section should be conducted in high-quality clinical settings.

AVAILABILITY OF DATA AND MATERIALS

Data of this study can be requested through the Zigong Fourth People's Hospital by E-mail (muguo@zg120.cn).

AUTHOR CONTRIBUTIONS

JLS and GM—conceptualization and literature search, manuscript preparation and revision. GM—methodology, study supervision and article final permission. JLS and XX—trial selection. JLS and XY—data analysis. QL and BL—data extraction. All authors have read and agreed to the published version of the manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

ACKNOWLEDGMENT

Thanks to Liu Xiao of Zigong Fourth People's Hospital for his help in the data analysis of this study.

FUNDING

This study was supported by Zigong Science and Technology Bureau (2021YLSF16). Sichuan Key Clinical Specialty project (2022-16).

CONFLICT OF INTEREST

All the authors declare that there was no conflict of interest. All authors and sponsors agreed to this publication.

SUPPLEMENTARY MATERIAL

Supplementary material associated with this article can be found, in the online version, at https://oss.signavitae. com/mre-signavitae/article/1777217407638487040/ attachment/Supplementary%20material.docx.

REFERENCES

- Bollag L, Lim G, Sultan P, Habib AS, Landau R, Zakowski M, et al. Society for obstetric anesthesia and perinatology: consensus statement and recommendations for enhanced recovery after cesarean. Anesthesia & Analgesia. 2021; 132: 1362–1377.
- [2] Mercier FJ, Augè M, Hoffmann C, Fischer C, Le Gouez A. Maternal hypotension during spinal anesthesia for caesarean delivery. Minerva Anestesiologica. 2013; 79: 62–73.
- ^[3] Kitaguchi M, Ida M, Naito Y, Akasaki Y, Kawaguchi M. Associated factors with umbilical arterial pH after cesarean delivery under spinal anesthesia: a retrospective cohort study. Brazilian Journal of Anesthesiology. 2022; 72: 466–471.
- [4] Ffrench-O'Carroll R, Tan T. National survey of vasopressor practices for management of spinal anaesthesia-induced hypotension during caesarean section. International Journal of Obstetric Anesthesia. 2021; 45: 156– 157.
- [5] Kinsella SM, Carvalho B, Dyer RA, Fernando R, McDonnell N, Mercier FJ, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia. 2018; 73: 71–92.
- [6] Noffsinger SR. Evidence-based prevention strategies for the management of spinal anesthesia-induced hypotension in healthy parturients undergoing elective cesarean delivery. The AANA Journal. 2022; 90: 311–316.
- [7] Park SK, Park DN, Kim YW, Yoo S, Kim WH, Lim YJ, et al. Colloid coload versus crystalloid coload to prevent maternal hypotension in women receiving prophylactic phenylephrine infusion during caesarean delivery: a randomised controlled trial. International Journal of Obstetric Anesthesia. 2022; 49: 103246.
- ^[8] Ngan Kee WD, Lee SW, Ng FF, Tan PE, Khaw KS. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology. 2015; 122: 736–745.
- [9] Huang Q, Wen G, Hai C, Zheng Z, Li Y, Huang Z, Huang B. A heightbased dosing algorithm of bupivacaine in spinal anesthesia for decreasing maternal hypotension in cesarean section without prophylactic fluid preloading and vasopressors: a randomized-controlled non-inferiority trial. Frontiers in Medicine. 2022; 9: 858115.
- [10] Stewart A, Fernando R, McDonald S, Hignett R, Jones T, Columb M. The dose-dependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia. Anesthesia & Analgesia. 2010; 111: 1230–1237.
- [11] Liu P, He H, Zhang SS, Liang Y, Gao ZJ, Yuan H, et al. Comparative efficacy and safety of prophylactic norepinephrine and phenylephrine in spinal anesthesia for cesarean section: a systematic review and metaanalysis with trial sequential analysis. Frontiers in Pharmacology. 2022; 13: 1015325.
- [12] Heesen M, Hilber N, Rijs K, Rossaint R, Girard T, Mercier FJ, et al. A systematic review of phenylephrine vs. noradrenaline for the management of hypotension associated with neuraxial anaesthesia in women undergoing caesarean section. Anaesthesia. 2020; 75: 800–808.
- [13] Singh PM, Singh NP, Reschke M, Ngan Kee WD, Palanisamy A, Monks DT. Vasopressor drugs for the prevention and treatment of hypotension during neuraxial anaesthesia for Caesarean delivery: a Bayesian network meta-analysis of fetal and maternal outcomes. British Journal of Anaesthesia. 2020; 124: e95–e107.
- [14] Mohta M, Bambode N, Chilkoti GT, Agarwal R, Malhotra RK, Batra P. Neonatal outcomes following phenylephrine or norepinephrine for treatment of spinal anaesthesia-induced hypotension at emergency caesarean section in women with fetal compromise: a randomised controlled study. International Journal of Obstetric Anesthesia. 2022; 49: 103247.
- ^[15] Singh A, Jain K, Goel N, Arora A, Kumar P. Neonatal outcomes

following prophylactic administration of phenylephrine or noradrenaline in women undergoing scheduled caesarean delivery. European Journal of Anaesthesiology. 2022; 39: 269–276.

- [16] Liu T, Cheng Z, Zou S, Xu C, Pan S, Zeng H, *et al.* Effect of weightadjusted phenylephrine, norepinephrine, and metaraminol for elective cesarean delivery on neonatal acid-base status: a randomized controlled trial. Drug Design, Development and Therapy. 2022; 16: 3215–3223.
- [17] Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. The BMJ. 2021; 372: n160.
- [18] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology. 2014; 14: 135.
- ^[19] Vallejo MC, Attaallah AF, Elzamzamy OM, Cifarelli DT, Phelps AL, Hobbs GR, *et al.* An open-label randomized controlled clinical trial for comparison of continuous phenylephrine versus norepinephrine infusion in prevention of spinal hypotension during cesarean delivery. International Journal of Obstetric Anesthesia. 2017; 29: 18–25.
- [20] Hasanin A, Amin S, Refaat S, Habib S, Zayed M, abdelwahab Y, *et al.* Norepinephrine versus phenylephrine infusion for prophylaxis against post-spinal anaesthesia hypotension during elective caesarean delivery: a randomised controlled trial. Anaesthesia Critical Care & Pain Medicine. 2019; 38: 601–607.
- [21] Biricik E, Karacaer F, Ünal İ, Sucu M, Ünlügenç H. The effect of epinephrine for the treatment of spinal-hypotension: comparison with norepinephrine and phenylephrine, clinical trial. Brazilian Journal of Anesthesiology. 2020; 70: 500–507.
- ^[22] Theodoraki K, Hadzilia S, Valsamidis D, Stamatakis E. Prevention of hypotension during elective cesarean section with a fixed-rate norepinephrine infusion versus a fixed-rate phenylephrine infusion. A double-blinded randomized controlled trial. International Journal of Surgery. 2020; 84: 41–49.
- [23] Eskandr AM, Ahmed AM, Bahgat NME. Comparative study among ephedrine, norepinephrine and phenylephrine infusions to prevent spinal hypotension during cesarean section. A randomized controlled doubleblind study. Egyptian Journal of Anaesthesia. 2021; 37: 295–301.
- [24] Goyal N, Goel K, Luthra N, Grewal A, Taneja A. Comparison of norepinephrine and phenylephrine infusions for maintenance of haemodynamics following subarachnoid block in lower segment caeserean section. Indian Journal of Anaesthesia. 2021; 65: 600–605.
- [25] Zhou Y, Yu Y, Chu M, Zhang Y, Yu X, Chen G. Comparison of metaraminol, phenylephrine, and norepinephrine infusion for prevention of hypotension during combined spinal-epidural anaesthesia for elective caesarean section: a three-arm, randomized, double-blind, non-inferiority trial. Drug Design, Development and Therapy. 2022; 16: 117–127.
- ^[26] Singh J, Singh J, Mitra S, Anand L, Goel B, Kaur M. Comparison of prophylactic phenylephrine and norepinephrine infusion on umbilical arterial pH and maternal blood pressure during spinal anaesthesia for caesarean delivery. Indian Journal of Anaesthesia. 2022; 66: S115–S121.
- ^[27] Guo L, Qin R, Ren X, Han C, Xue W, He L, *et al.* Prophylactic norepinephrine or phenylephrine infusion for bradycardia and post-spinal anaesthesia hypotension in patients with preeclampsia during Caesarean delivery: a randomised controlled trial. British Journal of Anaesthesia. 2022; 128: e305–e307.
- ^[28] Du W, Song Y, Li J, Zhou X, Xu Z, Liu Z. Comparison of prophylactic norepinephrine and phenylephrine infusions during spinal anaesthesia for primary caesarean delivery in twin pregnancies: a randomized doubleblinded clinical study. Drug Design, Development and Therapy. 2022; 16: 789–798.
- [29] Chen Z, Zhou J, Wan L, Huang H. Norepinephrine versus phenylephrine infusion for preventing postspinal hypotension during cesarean section for twin pregnancy: a double-blinded randomized controlled clinical trial. BMC Anesthesiology. 2022; 22: 17.
- [30] Mohta M, Garg A, Chilkoti GT, Malhotra RK. A randomised controlled trial of phenylephrine and noradrenaline boluses for treatment of postspinal hypotension during elective caesarean section. Anaesthesia. 2019; 74: 850–855.
- [31] Puthenveettil N, Sivachalam S, Rajan S, Paul J, Kumar L. Comparison of norepinephrine and phenylephrine boluses for the treatment of hypotension during spinal anaesthesia for caesarean section—a randomised

controlled trial. Indian Journal of Anaesthesia. 2019; 63: 995-1000.

- [32] Sharkey AM, Siddiqui N, Downey K, Ye XY, Guevara J, Carvalho JCA. Comparison of intermittent intravenous boluses of phenylephrine and norepinephrine to prevent and treat spinal-induced hypotension in cesarean deliveries: randomized controlled trial. Anesthesia & Analgesia. 2019; 129: 1312–1318.
- [33] Wang X, Mao M, Liu S, Xu S, Yang J. A comparative study of bolus norepinephrine, phenylephrine, and ephedrine for the treatment of maternal hypotension in parturients with preeclampsia during cesarean delivery under spinal anesthesia. Medical Science Monitor. 2019; 25: 1093–1101.
- [34] Cho WJ, Cho SY, Lee A. Systemic hemodynamic effects of norepinephrine versus phenylephrine in intermittent bolus doses during spinal anesthesia for cesarean delivery. Anesthesia and Pain Medicine. 2020; 15: 53–60.
- [35] Mohta M, R L, Chilkoti GT, Agarwal R, Malhotra RK. A randomised double-blind comparison of phenylephrine and norepinephrine for the management of postspinal hypotension in pre-eclamptic patients undergoing caesarean section. European Journal of Anaesthesiology. 2021; 38: 1077–1084.
- [36] Tiwari JP, Verma SJ, Singh AK. A prospective randomized study comparing the bolus doses of norepinephrine and phenylephrine for the treatment of spinal induced hypotension in cesarean section. Cureus. 2022; 14: e27166.
- [37] Rai AV, Prakash S, Chellani H, Mullick P, Wason R. Comparison of phenylephrine and norepinephrine for treatment of spinal hypotension during elective cesarean delivery—a randomised, double-blind study. Journal of Anaesthesiology Clinical Pharmacology. 2022; 38: 445–452.
- [38] Dong L, Dong Q, Song X, Liu Y, Wang Y. Comparison of prophylactic bolus norepinephrine and phenylephrine on hypotension during spinal anesthesia for cesarean section. International Journal of Clinical and Experimental Medicine. 2017; 10: 12315–12321.
- [39] Wang X, Mao M, Zhang SS, Wang ZH, Xu SQ, Shen XF. Bolus norepinephrine and phenylephrine for maternal hypotension during elective cesarean section with spinal anesthesia: a randomized, doubleblinded study. Chinese Medical Journal. 2020; 133: 509–516.
- [40] Ngan Kee WD, Lee SWY, Ng FF, Lee A. Norepinephrine or phenylephrine during spinal anaesthesia for Caesarean delivery: a randomised double-blind pragmatic non-inferiority study of neonatal outcome. British Journal of Anaesthesia. 2020; 125: 588–595.

- [41] Hassanin AS, El-Shahawy HF, Hussain SH, Bahaa Eldin AM, Elhawary MM, Elbakery M, *et al.* Impact of interval between induction of spinal anesthesia to delivery on umbilical arterial cord pH of neonates delivered by elective cesarean section. BMC Pregnancy and Childbirth. 2022; 22: 216.
- [42] Singh S, Lumbreras-Marquez MI, Farber MK, Xu X, Singh P, Gorman T, et al. Transient tachypnea of newborns is associated with maternal spinal hypotension during elective cesarean delivery: a retrospective cohort study. Anesthesia & Analgesia. 2019; 129: 162–167.
- [43] Malin GL, Morris RK, Khan KS. Strength of association between umbilical cord pH and perinatal and long term outcomes: systematic review and meta-analysis. The BMJ. 2010; 340: c1471.
- [44] Hoberg C, Klein C, Klein D, Meller C. Perinatal hypoxia and the risk of severe Molar-Incisor Hypomineralisation (MIH): a retrospective analysis of the pH value of umbilical arterial blood after birth. European Archives of Paediatric Dentistry. 2022; 23: 109–115.
- [45] Heesen M, Klöhr S, Rossaint R, Straube S. Prophylactic phenylephrine for caesarean section under spinal anaesthesia: systematic review and meta-analysis. Anaesthesia. 2014; 69: 143–165.
- [46] Liu JP, Pan ZB, Zhu M, Zhu GW, Song DB, Chen XZ, et al. Determination of the 90% effective dose of phenylephrine boluses to treat spinal anesthesia-induced hypotension in patients with severe preeclampsia during cesarean delivery: a pilot study. Drug Design, Development and Therapy. 2021; 15: 3765–3772.
- [47] Pauline A, Arthi K, Parameswari A, Vakamudi M, Manickam A. Prophylactic fixed-rate phenylephrine versus norepinephrine infusion in the prevention of post-spinal anesthesia hypotension during cesarean delivery. Cureus. 2023; 15: e41251.
- [48] Wang X, Shen X, Liu S, Yang J, Xu S. The efficacy and safety of norepinephrine and its feasibility as a replacement for phenylephrine to manage maternal hypotension during elective cesarean delivery under spinal anesthesia. BioMed Research International. 2018; 2018: 1869189.

How to cite this article: Jianli Song, Xi Xu, Qiang Li, Bin Lu, Xuan Yu, Guo Mu. Norepinephrine versus phenylephrine for managing maternal hypotension during cesarean delivery under spinal anesthesia: a meta-analysis of maternal and neonatal outcomes. Signa Vitae. 2024; 20(4): 1-14. doi: 10.22514/sv.2024.036.